GAVI partners with the International Federation of Pharmaceutical Manufacturers Association to provide the right vaccines in the right amounts to the developing country market
GAVI's partnership with vaccine companies in the industrialised world provides a critical bridge for harnessing their research and technical expertise to making and supplying vaccines that address the needs of developing countries.
The Alliance's partners among industrialised country vaccine manufacturers are members of the International Federation of Pharmaceutical Manufacturers Association. Building on their engagement in the Children's Vaccine Initiative launched in 1990, IFPMA members have worked in partnership with the GAVI Alliance since its launch in 2000, suppling vaccines to a number of key GAVI-supported programmes:
- Crucell supplied the first internationally-available, fully liquid pentavalent (5-in-1) vaccine Quinvaxem™. Over half a billion doses of liquid pentavalent vaccine have been requested for 2009-2012.
- GlaxoSmithKline was GAVI's main supplier of pentavalent and tetravalent vaccine in its first five years and has committed to supply 300 million doses of pneumococcal vaccine to GAVI over 10 years.
- Merck's Foundation provides funding for the Merck Vaccine Network - Africa. Merck donated hepatitis B vaccine in support of GAVI and is providing rotavirus vaccination for all infants in Nicaragua for a three-year period.
- Sanofi Pasteur supports GAVI's Yellow fever initiative for Africa.
- Pfizer introduction of pneumococcal vaccine to Rwanda in April 2009, the first use in a GAVI-eligible country. Under a 2008 proposal by Wyeth (subsequently acquired by Pfizer) committed to donate more than three million doses to immunisation in Rwanda and The Gambia.
Advance Market Commitment
Role on the GAVI Alliance Board
Board members representing the industrialised countries' vaccine industry always come from the International Federation of Pharmaceutical Manufacturers (IFPMA). This represents more than 55 national industry associations members, including Crucell, GlaxoSmithKline, Merck & Co., Novartis, Sanofi Pasteur, the vaccines division of Sanofi-Aventis, and Pfizer.
Cooperation with GAVI has included participating in innovative financing mechanisms, such as the Advance Market Commitment (AMC), that provides a platform for investing in the development of a sustainable supply of breakthrough vaccines.
This enables developing countries to receive vaccines more quickly than would have been possible if left to normal market mechanisms and at prices far lower than those paid in developed countries.
In addition to supplying vaccines to GAVI-supported programmes, IFPMA members have helped to develop technologies that facilitate the distribution of vaccines and the way they are administered. They further support GAVI's immunisation strategy by contributing to the education of public health officials and by working to engage other private sector organisations in GAVI's mission.
What the Alliance offers industrialised country vaccine companies
Through the Alliance, vaccine companies receive:
- forecasts of country vaccine demand: essential to planning and scaling-up production;
- vaccine product profiles based on the results of surveillance: these help companies tailor vaccines to better fit the requirements of developing countries (a role that passed to the WHO in 2010 with the creation of the Immunisation Practice Advisory Board).